NCATS Research & Development Day will provide the unique opportunity to showcase the projects and technologies that have been incubating in a variety of NCATS drug development programs, including Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs), to an audience of biopharmaceutical companies, venture capital, angel investors, foundations, and others. The object is to connect our collaborators with strategic partners that will provide financial and technical support to bring potential novel therapeutics to patients. The event will be held:

Thursday, September 12, 2013
Novartis Institutes for Biomedical Research
        Cambridge, Massachusetts

A key aspect of the mission of the Division of Preclinical Innovation (DPI) at NCATS is to foster preclinical and early clinical development of therapeutic candidates. Using a collaborative model that teams NCATS drug development scientists with external disease-area experts, DPI provides critical scientific and non-dilutive financial resources to move therapeutic candidates from the preclinical stage of drug development to the filing of an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA).
To advance projects, DPI actively seeks strategic partners to adopt and advance its preclinical and early clinical candidates through the final phases of clinical development.
Supported By
U.S. Department of Health and Human Services National Center for Advancing Translational Sciences NIBR